Acute graft-versus-host disease (GVHD) is a common immune complication that can occur
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …

Allogeneic haematopoietic stem cell transplantation is used to treat a variety of disorders,
but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past …

Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …

Allogeneic haematopoietic stem-cell transplantation (SCT) is a curative therapy for
haematological malignancies and inherited disorders of blood cells, such as sickle-cell …

Mesenchymal stromal cells or mesenchymal stem cells (MSCs) have captured considerable
scientific and public interest because of their potential to limit physical and immune injury, to …

Over the past 5 years, many novel approaches to early diagnosis, prevention, and treatment
of acute graft-versus-host disease (aGVHD) have been translated from the bench to the …

Graft-versus-host disease (GVHD) is caused by alloreactive donor T cells that trigger host
tissue injury. GVHD develops over weeks or months, but how this immune response is …

Dendritic cells (DCs) are a heterogeneous fraction of rare hematopoietic cells that coevolved
with the formation of the adaptive immune system. DCs efficiently process and present …

The presentation pathways by which allogeneic peptides induce graft-versus-host disease
(GVHD) are unclear. We developed a bone marrow transplant (BMT) system in mice …

Allogeneic hematopoietic SCT (HSCT) is an established treatment for some children with life-
threatening hematological disease, immune deficiencies and inborn errors of metabolism …